Views
1 year ago

gwpfdb7

gwpfdb7

The Promise of the

The Promise of the Pipeline The rapid pace of scientific advances is giving patients unprecedented hope. Researchers are leveraging growing knowledge of the biological basis of disease and harnessing technological advances across the biopharmaceutical ecosystem to usher in a new era of treatment possibilities. This commitment to bringing new medicines to patients is evidenced by the robust pipeline of medicines currently in development. Today, more than 7,000 medicines targeting a broad array of disease areas and conditions are in clinical development around the world (see Figure 21). 1 Many of these medicines have the potential to meet substantial unmet patient need. In fact, experts estimate 70% are potential first-in-class medicines with a mechanism of action distinct from any other marketed drug. 2 Researchers are also leveraging their understanding of the molecular basis of disease to develop a new wave of targeted therapies. 62 The Promise of the Pipeline

Today, 42% of medicines in development have the potential to be personalized medicines, and 73% of cancer medicines have the potential to be personalized medicines. 3 For patients lacking treatment options or those for whom existing therapies have been unsuccessful, these potential medicines hold great promise in helping them live longer, healthier lives. But what’s more, these medicines offer to alter the trajectory of some of the most complex and challenging diseases of our time. EXAMINING THE PIPELINE Novel scientific approaches employed across the biopharmaceutical pipeline are giving patients new sources of hope. Here are just a few examples of how researchers are exploring innovative strategies to deliver new medicines to patients across a broad range of complex diseases and conditions. Multiple Sclerosis Multiple sclerosis (MS) is a debilitating, chronic autoimmune disorder, which generally leads to disability. In MS, the immune system mistakenly attacks myelin, a substance that coats nerve fibers, resulting in a disruption of communication between the brain and the body. Common symptoms include fatigue, walking difficulties, numbness, spasticity, muscle stiffness, weakness, vision problems, sexual problems, bowel problems, pain, and cognitive and emotional FIGURE 21: More Than 7,000 Medicines in Development Globally Biopharmaceutical researchers are working on new medicines* for many diseases, including: *Defined as single products that are counted exactly once regardless of the number of indications pursued Source: Adis R&D Insight Database. Accessed March 2016. The Promise of the Pipeline 63

PHOTO TO BE INSERTED
Fiction?
Making a Killing AMENDED - Animal Aid
I've Got Nothing to Lose by Trying It - Sense About Science
Eli Lilly and Company Corporate Citizenship ... - SocialFunds.com
WHO-Medicines-Report-FINAL2015
Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.
RxD-Magazine-FINAL-Online